Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 dexpramipexole versus placebo in amyotrophic lateral sclerosis
NL-OMON38301Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Dexpramipexole with Placebo (2 arms). Primary endpoints: ALS Functional Rating Scale-Revised through 12 months and Time to death through 12 months. Started Jun 2011; status: active, not recruiting.
02
Drugs
dexpramipexole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON38301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38301.